GLP-1 and Cardiovascular Risk Reduction Mechanisms
Multiple pathways in heart and blood vessels explain how GLP-1 drugs cut cardiovascular risk.
Rafael Ibrahim
Section
Emerging GLP-1 Indications
13 stories in Emerging GLP-1 Indications.
GLP-1 Agonists in Non-Alcoholic Fatty Liver Disease
GLP-1 drugs reduce liver fat and inflammation, but struggle to reverse fibrosis.
Kwame Delgado
GLP-1 Effects on Sleep Architecture and Metabolic Recovery
GLP-1 drugs reshape sleep architecture through brain circuits most trials never measured.
Freya Ashworth
GLP-1 Receptors in Nicotine and Opioid Craving Reduction
GLP-1 drugs reduce craving for nicotine and opioids by rewiring the brain's reward circuitry itself.
Rohan Park
GLP-1 Agonists and Parkinson's Disease Neuroprotection
Diabetes drugs show promise in lab but fail to slow Parkinson's in patients.
Priya Costa
GLP-1 Receptor Activation and Opioid Craving Reduction
Brain scans reveal why these diabetes drugs reduce opioid craving.
Lucia Zola
Obesity-Brain Axis and Hypothalamic Inflammation
Inflammation in the brain's appetite center may explain why obesity resists conventional treatment.
Dmitri Sinclair
GLP-1 Drugs and Parkinson's Disease Neuroprotection
GLP-1 drugs show promise for Parkinson's through multiple protective pathways in dopamine neurons.
Estelle Vance
GLP-1 Signaling in Alzheimer's Disease Models
Diabetes drugs show unexpected promise in Alzheimer's models.
Soren Kowalski
GLP-1 Signaling in Alzheimer's Disease Research
Gut-derived receptor shows promise for slowing Alzheimer's brain shrinkage in early trials.
Sofia Whitfield
GLP-1 Receptor Agonists in Alcohol Use Disorder
Nose-to-brain delivery could unlock GLP-1's potential for alcohol addiction.
Simone Contreras
GLP-1 Receptors and Dopamine Pathways in Addiction
The brain's reward circuitry uses GLP-1 to dampen dopamine surges from drugs and alcohol.
Malik Sinclair
GLP-1 Agonists in Alcohol Use Disorder Research
Diabetes drugs show promise against cravings by targeting alcohol's reward pathways.
Ezra Sabatini